首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1390691

血友病市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: 2023年11月24日 | 出版商:

IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

概要

2022年全球血友病市場規模達117億美元。展望未來， IMARC Group預計到2028年市場規模將達到223億美元，2022-2028年複合年成長率（CAGR）為11.35%。

血友病是一種影響血液凝固過程的遺傳性醫學疾病，其中血液凝固異常。它會導致受傷、手術和牙科手術後自發性出血和過度出血、容易瘀傷和滲血。它是由遺傳性缺乏凝血因子引起的，由於缺乏足夠的凝血蛋白，凝血因子會減慢血液凝固。可以使用藥物、替代療法和注射凝血因子或血漿來治療。其治療重點是替換缺失的蛋白質和預防併發症。

血友病市場趨勢：

全球血友病患者數量的增加和個體遺傳異常發生率的增加是積極影響市場的關鍵因素之一。此外，疾病診斷率的上升以及血友病預防性治療的日益普及，為領先的市場參與者提供了利潤豐厚的成長機會。除此之外，各國管理機構正在組織大量活動，以宣傳早期診斷的好處，並遵循適當的程序來促進新生兒的早期篩檢，這為市場創造了積極的前景。此外，由於治療方案的可用性有限，他們擴大資助研究和開發 (R&D) 活動。此外，領先的產業參與者正致力於引進技術先進的診斷工具和療法，以提高血友病治療的功效和準確性，這提供了良好的市場前景。此外，預計在全球範圍內擴大建立專門的血友病治療中心（HTC）的大量投資將推動市場的發展。

本報告回答的關鍵問題

2022年全球血友病市場規模有多大？
2023-2028年全球血友病市場的預期成長率是多少？
推動全球血友病市場的關鍵因素是什麼？
COVID-19 對全球血友病市場有何影響？
全球血友病市場按類型分類是怎樣的？
根據治療方法，全球血友病市場的細分如何？
基於該療法的全球血友病市場的詳細情形如何？
全球血友病市場的重點區域有哪些？
全球血友病市場的主要參與者/公司有哪些？

北美洲
- 美國
  - 市場走向
  - 市場預測
- 加拿大
  - 市場走向
  - 市場預測
亞太
- 中國
  - 市場走向
  - 市場預測
- 日本
  - 市場走向
  - 市場預測
- 印度
  - 市場走向
  - 市場預測
- 韓國
  - 市場走向
  - 市場預測
- 澳洲
  - 市場走向
  - 市場預測
- 印尼
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
歐洲
- 德國
  - 市場走向
  - 市場預測
- 法國
  - 市場走向
  - 市場預測
- 英國
  - 市場走向
  - 市場預測
- 義大利
  - 市場走向
  - 市場預測
- 西班牙
  - 市場走向
  - 市場預測
- 俄羅斯
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
拉丁美洲
- 巴西
  - 市場走向
  - 市場預測
- 墨西哥
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
中東和非洲
- 市場走向
- 按國家/地區分類的市場細分
- 市場預測

第 10 章：SWOT 分析

概述
優勢
弱點
機會
威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

概述
買家的議價能力
供應商的議價能力
競爭程度
新進入者的威脅
替代品的威脅

第 13 章：價格分析

第14章：競爭格局

市場結構
關鍵參與者
關鍵參與者簡介
- Baxter International Inc.
- Bayer AG
- BioMarin Pharmaceutical Inc.
- CSL Behring (CSL Limited)
- F. Hoffmann-La Roche AG
- Grifols SA
- Kedrion SpA
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited

簡介目錄圖表

Product Code: SR112023A4508

Abstract

The global hemophilia market size reached US$ 11.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.35% during 2022-2028.

Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.

Hemophilia Market Trends:

The increasing number of hemophilic patients and rising occurrences of genetic abnormalities among individuals across the globe represents one of the key factors positively influencing the market. In addition, the rising diagnosis rate of the illness and the growing popularity of prophylactic treatment to cure hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, governing agencies of various countries are organizing numerous campaigns to spread awareness about the benefits of early diagnosis and following appropriate procedures to facilitate the early screening of neonates, which is creating a positive outlook for the market. Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment and therapy.

Breakup by Type:

Hemophilia A

Hemophilia B

Hemophilia C

Others

Hemophilia A represents the largest market segment due to the rising prevalence of hemophilia A among individuals across the globe and the increasing requirement for patient care.

Breakup by Treatment:

On-Demand

Prophylaxis

On-demand treatment currently holds the largest market share as it is highly beneficial for patients with mild or moderate hemophilia who bleed less often.

Breakup by Therapy:

Replacement Therapy

ITI Therapy

Gene Therapy

Replacement therapy is a standard therapy used to treat hemophilia as it helps replace the missing clotting factor among patients. It involves offering the missing clotting factor to patients from an external source.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market due to the increasing government spending on healthcare and research and development (R&D) activities, along with the presence of various leading players in the country.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report

1. What was the size of the global hemophilia market in 2022?
2. What is the expected growth rate of the global hemophilia market during 2023-2028?
3. What are the key factors driving the global hemophilia market?
4. What has been the impact of COVID-19 on the global hemophilia market?
5. What is the breakup of the global hemophilia market based on the type?
6. What is the breakup of the global hemophilia market based on the treatment?
7. What is the breakup of the global hemophilia market based on the therapy?
8. What are the key regions in the global hemophilia market?
9. Who are the key players/companies in the global hemophilia market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Hemophilia Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Hemophilia A
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Hemophilia B
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Hemophilia C
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Treatment

7.1 On-Demand
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Prophylaxis
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Therapy

8.1 Replacement Therapy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 ITI Therapy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Gene Therapy
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Baxter International Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Bayer AG
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 BioMarin Pharmaceutical Inc.
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 CSL Behring (CSL Limited)
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 F. Hoffmann-La Roche AG
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
- 14.3.6 Grifols S.A.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Kedrion S.p.A.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
- 14.3.8 Novo Nordisk A/S
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Octapharma AG
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 SWOT Analysis
- 14.3.10 Pfizer Inc.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 Sanofi S.A.
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis
- 14.3.12 Takeda Pharmaceutical Company Limited
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio
  - 14.3.12.3 Financials
  - 14.3.12.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Hemophilia Market: Major Drivers and Challenges
Figure 2: Global: Hemophilia Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Hemophilia Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Hemophilia Market: Breakup by Type (in %), 2022
Figure 5: Global: Hemophilia Market: Breakup by Treatment (in %), 2022
Figure 6: Global: Hemophilia Market: Breakup by Therapy (in %), 2022
Figure 7: Global: Hemophilia Market: Breakup by Region (in %), 2022
Figure 8: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Hemophilia (Other Types) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Hemophilia (On-Demand) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: North America: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: North America: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: United States: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: United States: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Canada: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Canada: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Asia-Pacific: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: China: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: China: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Japan: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Japan: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: India: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: India: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: South Korea: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: South Korea: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Australia: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Australia: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Indonesia: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Indonesia: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Others: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Europe: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Europe: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Germany: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Germany: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: France: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: France: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: United Kingdom: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Italy: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Italy: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Spain: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Spain: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Russia: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Russia: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Others: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Latin America: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Latin America: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Brazil: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Brazil: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Mexico: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Mexico: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Others: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Middle East and Africa: Hemophilia Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2022
Figure 74: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Global: Hemophilia Industry: SWOT Analysis
Figure 76: Global: Hemophilia Industry: Value Chain Analysis
Figure 77: Global: Hemophilia Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hemophilia Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million US$), 2023-2028
Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million US$), 2023-2028
Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Hemophilia Market: Competitive Structure
Table 7: Global: Hemophilia Market: Key Players

02-2729-4219

+886-2-2729-4219